• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

For a lot of people suffering from depression, traditional therapy and medication are ineffective. Personalized treatment could be the solution.

Cue is an intervention platform that converts sensor data collected from smartphones into customized micro-interventions to improve mental health. We looked at the best-fitting personal ML models to each subject using Shapley values to determine their features and predictors. The results revealed distinct characteristics that changed mood in a predictable manner over time.

Predictors of Mood

Depression is the leading cause of mental illness around the world.1 Yet only half of those suffering from the condition receive treatment. To improve outcomes, healthcare professionals must be able to identify and treat patients who are most likely to benefit from certain treatments.

The treatment of depression can be personalized to help. Utilizing sensors on mobile phones and an artificial intelligence voice assistant, and other digital tools, researchers at the University of Illinois Chicago (UIC) are working on new ways to determine which patients will benefit from the treatments they receive. Two grants totaling more than $10 million will be used to identify the biological and behavioral factors that predict response.

The majority of research conducted to date has focused on clinical and sociodemographic characteristics. These include demographic variables such as age, gender and educational level, clinical characteristics like symptoms severity and comorbidities and biological markers like neuroimaging and genetic variation.

While many of these variables can be predicted by the information available in medical records, very few studies have employed longitudinal data to explore the factors that influence mood in people. Few also take into account the fact that moods vary significantly between individuals. Therefore, it is crucial meds to treat depression devise methods that allow for the determination and quantification of the individual differences between mood predictors and treatment effects, for instance.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. This enables the team to create algorithms that can detect distinct patterns of behavior and emotions that differ between individuals.

In addition to these modalities the team also developed a machine-learning algorithm to model the dynamic variables that influence each person's mood. The algorithm blends the individual differences to create a unique "digital genotype" for each participant.

This digital phenotype was associated with CAT DI scores that are a psychometrically validated symptoms severity scale. However, the correlation was weak (Pearson's r = 0.08, BH-adjusted P-value of 3.55 x 10-03) and varied widely among individuals.

Predictors of symptoms

Depression is the leading cause of disability around the world, but it is often not properly diagnosed and treated. In addition an absence of effective interventions and stigma associated with depression disorders hinder many people from seeking help.

To aid in the development of a personalized treatment plan, identifying factors that predict the severity of symptoms is crucial. Current prediction methods rely heavily on clinical interviews, which are not reliable and only detect a few characteristics that are associated with depression.

Machine learning can enhance the accuracy of diagnosis and treatment for depression by combining continuous, digital behavioral patterns gathered from sensors on smartphones with a valid mental health tracker online (the Computerized Adaptive Testing Depression Inventory CAT-DI). These digital phenotypes allow continuous, high-resolution measurements as well as capture a variety of distinctive behaviors and activity patterns that are difficult to document through interviews.

The study involved University of California Los Angeles students who had mild to severe depression symptoms who were enrolled in the Screening and treatment resistant anxiety and depression for Anxiety and Depression program29, which was developed as part of the UCLA Depression Grand Challenge. Participants were directed to online support or clinical care depending on the severity of their depression. Those with a score on the CAT-DI of 35 65 were given online support via a coach and those with a score 75 patients were referred to in-person psychotherapy.

At the beginning, participants answered the answers to a series of questions concerning their personal demographics and psychosocial features. The questions included age, sex and education, marital status, financial status, whether they were divorced or not, current suicidal ideas, intent or attempts, as well as how often they drank. Participants also scored their level of depression symptom severity on a scale of 0-100 using the CAT-DI. CAT-DI assessments were conducted each other week for participants that received online support, and every week for those who received in-person care.

Predictors of Treatment Reaction

Research is focusing on personalization of treatment for depression. Many studies are focused on finding predictors that can help doctors determine the most effective drugs to treat each patient. Particularly, pharmacogenetics is able to identify genetic variations that affect the way that the body processes antidepressants. This lets doctors select the medication that are most likely to work for every patient, minimizing the amount of time and effort required for trial-and-error treatments and avoid any negative side consequences.

Another promising method is to construct models of prediction using a variety of data sources, such as clinical information and neural imaging data. These models can then be used to identify the best combination of variables predictors of a specific outcome, such as whether or not a particular medication will improve mood and symptoms. These models can also be used to predict a patient's response to a private treatment for depression they are currently receiving which allows doctors to maximize the effectiveness of their treatment currently being administered.

A new era of research utilizes machine learning techniques, such as supervised learning and classification algorithms (like regularized logistic regression or tree-based techniques) to combine the effects of many variables to improve predictive accuracy. These models have been shown to be useful in predicting outcomes of treatment, such as response to antidepressants. These approaches are gaining popularity in psychiatry, and it is expected that they will become the standard for future clinical practice.

Research into depression's underlying mechanisms continues, as do ML-based predictive models. Recent research suggests that the disorder is connected with dysfunctions in specific neural circuits. This suggests that an the treatment for depression and treatment will be individualized built around targeted therapies that target these neural circuits to restore normal function.

Internet-based interventions are an option to accomplish this. They can provide a more tailored and individualized experience for patients. For example, one study found that a program on the internet was more effective than standard care in reducing symptoms and ensuring an improved quality of life for people suffering from MDD. A controlled study that was randomized to a customized treatment for depression showed that a significant number of participants experienced sustained improvement and had fewer adverse negative effects.

Predictors of Side Effects

In the treatment of depression, one of the most difficult aspects is predicting and identifying the antidepressant that will cause no or minimal negative side negative effects. Many patients are prescribed various medications before settling on a treatment that is both effective and well-tolerated. Pharmacogenetics offers a fresh and exciting method of selecting antidepressant medications that is more efficient and targeted.

There are many predictors that can be used to determine which antidepressant should be prescribed, including genetic variations, phenotypes of the patient like gender or ethnicity, and the presence of comorbidities. However it is difficult to determine the most reliable and accurate predictive factors for a specific treatment is likely to require randomized controlled trials with considerably larger samples than those that are typically part of clinical trials. This is due to the fact that it can be more difficult to identify interactions or moderators in trials that comprise only a single episode per person rather than multiple episodes over time.

Furthermore to that, predicting a patient's reaction will likely require information on the severity of symptoms, comorbidities and the patient's own perception of effectiveness and tolerability. Presently, only a handful of easily identifiable sociodemographic and clinical variables are believed to be reliably associated with the severity of MDD factors, including gender, age race/ethnicity, SES BMI and the presence of alexithymia and the severity of depressive symptoms.

Many issues remain to be resolved in the use of pharmacogenetics to treat depression. It is crucial to be able to comprehend and understand the definition of the genetic mechanisms that underlie depression treatment centers, as well as an accurate definition of an accurate indicator of the response to treatment. Ethics, such as privacy, and the responsible use of genetic information must also be considered. In the long term pharmacogenetics can offer a chance to lessen the stigma associated with mental health treatment resistant depression treatment (learn the facts here now) and improve the outcomes of those suffering with depression. However, as with all approaches to psychiatry, careful consideration and planning is necessary. At present, it's ideal to offer patients a variety of medications for depression that are effective and encourage patients to openly talk with their physicians.